Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2015-05-05 | "Dr. Kelley has been developing drugs in oncology and immunology for over 25 years... Dr. Kelley received her M.D. from Duke University School of Medicine." |
| 2016-04-28 | "Dr. Kelley received her M.D. from Duke University School of Medicine... qualified... due to her experience in life sciences and clinical development." |
| 2018-05-31 | "Dr. Kelley has been developing drugs in oncology and immunology for over 25 years... Dr. Kelley received her M.D. from Duke University School of Medicine." |
| 2019-04-30 | "Dr. Kelley received her M.D. from Duke University School of Medicine." |
| 2021-05-14 | “Dr. Kelley received her M.D. from Duke University School of Medicine.” |
| 2022-04-29 | “Dr. Kelley received her M.D. from Duke University School of Medicine.” |
| 2023-04-27 | "Dr. Kelley received her M.D. from Duke University School of Medicine." |
| 2024-04-26 | “Dr. Kelley has been developing drugs in oncology and immunology for over 35 years.” |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-04-08